Biosimilar Reviews Complicated By Improving Analytics, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
With the abundance of data coming in now, FDA must understand structure/function better so it can determine which product attributes matter and which do not, Office of Biotechnology Products Director Steven Kozlowski says.